Summit Therapeutics shares rise as ivonescimab lung cancer survival data improves

SMMT Summit Therapeutics Inc

$17.31 +0.23%

View chart & analysis →

RCUS -1.86%

1. 1Summit Therapeutics (SMMT) shares rose 3% on Wednesday after the company released updated overall survival data from the Phase 3 HARMONi trial of ivonescimab combination therapy.
2. 2The hazard ratio for death in Western patients was 0.76, consistent with the Asia results, and follow-up extended from 9.2 months to 23.2 months.
3. 3The updated data has been submitted to the FDA for review of the Biologics License Application, with a PDUFA target date of November 14 and no new safety concerns.

Source InvestorsHub +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →